Cytokinetics, Incorporated (CYTK)
Automate Your Wheel Strategy on CYTK
With Tiblio's Option Bot, you can configure your own wheel strategy including CYTK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CYTK
- Rev/Share 0.7269
- Book/Share -4.3433
- PB -15.6861
- Debt/Equity -1.9921
- CurrentRatio 6.8758
- ROIC -0.43
- MktCap 8105982790.0
- FreeCF/Share -3.7787
- PFCF -17.879
- PE -10.871
- Debt/Assets 0.7226
- DivYield 0
- ROE 2.3287
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | CYTK | Raymond James | -- | Market Perform | -- | -- | July 30, 2025 |
| Initiation | CYTK | Barclays | -- | Overweight | -- | $55 | April 24, 2025 |
| Initiation | CYTK | Citigroup | -- | Buy | -- | $86 | Feb. 7, 2025 |
| Initiation | CYTK | Stifel | -- | Buy | -- | $80 | Jan. 22, 2025 |
News
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
Published: September 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 24, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period").
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines – CYTK
Published: September 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Deadline Alert: Cytokinetics, Incorporated (CYTK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: September 24, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR CYTOKINETICS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALL.
Read More
CYTK INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In CYTK To Contact Him Directly To Discuss Their Options
Published: September 24, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept.
Read More
Deadline Approaching: Cytokinetics, Incorporated (CYTK) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Published: September 23, 2025 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CYTOKINETICS, INCORPORATED (CYTK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines - CYTK
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate ("Cytokinetics" or the "Company") (NASDAQ: CYTK).
Read More
Class Action Filed Against Cytokinetics, Incorporated (CYTK) Seeking Recovery for Investors – Contact Levi & Korsinsky
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit.
Read More
Law Offices of Frank R. Cruz Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action
Published: September 22, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action.
Read More
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ: CYTK) and certain of its officers.
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: September 19, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cytokinetics To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Cytokinetics (CYTK) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). The lawsuit alleges Defendants represented that Cytokinetics expected approval from the U.S. Food and Drug Administration ("FDA") for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy ("REMS") that could delay the regulatory process.
Read More
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
Published: September 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the offering was increased from the previously announced offering size of $550.0 million.
Read More
Cytokinetics, Incorporated (CYTK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Cytokinetics, Incorporated (NASDAQ:CYTK ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Fady Malik - Executive Vice President of Research & Development Andrew Callos - Executive VP & Chief Commercial Officer Sung Lee - EVP & CFO Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst All right. Great. I'm Max Skor, a biotech analyst with Morgan Stanley.
Read More
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.
Read More
Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential
Published: September 02, 2025 by: Seeking Alpha
Sentiment: Positive
MAPLE-HCM establishes Cytokinetics, Incorporated's aficamten as superior to metoprolol in obstructive HCM, reframing it as a potential first-line, best-in-class therapy. Commercial potential is significant, with U.S. peak sales scenarios ranging from ~$1.2B–$3.5B (net) depending on adoption, and higher if global and non-obstructive HCM are included. Differentiation vs. Camzyos (mavacamten) lies in aficamten's shorter half-life, faster titration, and cleaner safety profile, which may drive higher physician preference despite BMS's head start.
Read More
Cytokinetics, Incorporated - Exploring The Changing Treatment Paradigm Transcript
Published: September 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Cytokinetics, Incorporated -Exploring The Changing Treatment Paradigm Transcript Company Participants Diane Weiser - Senior Vice President of Corporate Affairs Fady Malik - Executive Vice President of Research & Development Daniel Jacoby Robert I. Blum - CEO, President & Director Conference Call Participants Pablo García-Pavia - Head, Heart Failure and Inherited Cardiac Diseases Unit, Hospital Universatario Carolyn Ho - Medical Director of the Cardiovascular Genetic Center Ahmad Masri - Cardiomyopathy Section Head and Director, Hypertrophic Cardiomyopathy Center Anjali Owens - Medical Director, Inherited Cardiac Disease Presentation Diane Weiser Senior Vice President of Corporate Affairs Welcome, everyone, and thanks for joining.
Read More
Cytokinetics Stock Jumps. The Biotech's Heart Drug Wows.
Published: September 02, 2025 by: Barrons
Sentiment: Positive
Trial results for aficamten were presented to cardiologists over the weekend. One analyst said the drug could be “best-in-class therapy.
Read More
Cytokinetics Merits A Speculative Buy Rating
Published: July 25, 2025 by: Seeking Alpha
Sentiment: Positive
Cytokinetics continues to near unaminous positive analyst sentiment, with most price targets well above current levels, reflecting strong growth expectations. The company's NDA around its lead drug candidate was delayed by three months recently. However, Cytokinetics maintains a robust cash position of $1.1 billion, supporting ongoing operations and R&D. If all goes according to schedule, Cytokinetics should receive the first of many FDA approvals late this year and has several potential catalysts on the horizon.
Read More
Shareholders That Lost Money on Cytokinetics, Incorporated(CYTK) Should Contact Levi & Korsinsky about Securities Fraud Investigation - CYTK
Published: June 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Read More
Did Cytokinetics, Incorporated Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - CYTK
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Read More
Cytokinetics, Incorporated INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Cytokinetics, Incorporated (CYTK)
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Read More
Cytokinetics, Incorporated (CYTK) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Read More
Protect Your Investment: Contact Levi & Korsinsky About the Cytokinetics, Incorporated (CYTK) Investigation
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK). Investors who purchased Cytokinetics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CYTK.
Read More
Lost Money on Cytokinetics, Incorporated (CYTK)? Contact Levi & Korsinsky to Protect Your Rights
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Read More
Ongoing Investigation: Cytokinetics, Incorporated (CYTK) May Have Misled Shareholders - Levi & Korsinsky Investigates
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK). Investors who purchased Cytokinetics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CYTK.
Read More
ATTENTION Cytokinetics, Incorporated (CYTK) Investors: Possible Fraud - Contact Levi & Korsinsky Today
Published: May 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect
Published: May 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK). Investors who purchased Cytokinetics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CYTK.
Read More
About Cytokinetics, Incorporated (CYTK)
- IPO Date 2004-04-30
- Website https://www.cytokinetics.com
- Industry Biotechnology
- CEO Robert I. Blum
- Employees 498